Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke

Scientific rationale and available evidence

Arthur M. Pancioli, Thomas G Brott

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Acute ischaemic stroke is the result of an abrupt interruption of focal cerebral blood flow. In the majority of cases, this interruption is caused by an acute thromboembolism. Based on clinical experience in the treatment of acute coronary syndromes, platelet glycoprotein (GP) IIb/IIIa receptor antagonists alone, in combination with reduced doses of thrombolytic agents, or as complementary therapy for short-term mechanical interventions merit consideration as a class of agents with potential use in ischaemic stroke. Research to date and extrapolation from the cardiac literature suggest significant, but as yet unproven, potential for the use of GP IIb/IIIa receptor antagonists in the treatment of acute ischaemic stroke. This potential exists both at the site of the thromboembolic occlusion and at the distal microvascular level. This article reviews the scientific rationale and available evidence for the potential use of platelet GP IIb/IIIa receptor antagonists in acute ischaemic stroke.

Original languageEnglish (US)
Pages (from-to)981-988
Number of pages8
JournalCNS Drugs
Volume18
Issue number14
DOIs
StatePublished - 2004

Fingerprint

Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Stroke
Cerebrovascular Circulation
Fibrinolytic Agents
Thromboembolism
Therapeutics
Acute Coronary Syndrome
Complementary Therapies
Research

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

@article{ea433b40f9c04b078c873ea29ff52caa,
title = "Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: Scientific rationale and available evidence",
abstract = "Acute ischaemic stroke is the result of an abrupt interruption of focal cerebral blood flow. In the majority of cases, this interruption is caused by an acute thromboembolism. Based on clinical experience in the treatment of acute coronary syndromes, platelet glycoprotein (GP) IIb/IIIa receptor antagonists alone, in combination with reduced doses of thrombolytic agents, or as complementary therapy for short-term mechanical interventions merit consideration as a class of agents with potential use in ischaemic stroke. Research to date and extrapolation from the cardiac literature suggest significant, but as yet unproven, potential for the use of GP IIb/IIIa receptor antagonists in the treatment of acute ischaemic stroke. This potential exists both at the site of the thromboembolic occlusion and at the distal microvascular level. This article reviews the scientific rationale and available evidence for the potential use of platelet GP IIb/IIIa receptor antagonists in acute ischaemic stroke.",
author = "Pancioli, {Arthur M.} and Brott, {Thomas G}",
year = "2004",
doi = "10.2165/00023210-200418140-00003",
language = "English (US)",
volume = "18",
pages = "981--988",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "14",

}

TY - JOUR

T1 - Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke

T2 - Scientific rationale and available evidence

AU - Pancioli, Arthur M.

AU - Brott, Thomas G

PY - 2004

Y1 - 2004

N2 - Acute ischaemic stroke is the result of an abrupt interruption of focal cerebral blood flow. In the majority of cases, this interruption is caused by an acute thromboembolism. Based on clinical experience in the treatment of acute coronary syndromes, platelet glycoprotein (GP) IIb/IIIa receptor antagonists alone, in combination with reduced doses of thrombolytic agents, or as complementary therapy for short-term mechanical interventions merit consideration as a class of agents with potential use in ischaemic stroke. Research to date and extrapolation from the cardiac literature suggest significant, but as yet unproven, potential for the use of GP IIb/IIIa receptor antagonists in the treatment of acute ischaemic stroke. This potential exists both at the site of the thromboembolic occlusion and at the distal microvascular level. This article reviews the scientific rationale and available evidence for the potential use of platelet GP IIb/IIIa receptor antagonists in acute ischaemic stroke.

AB - Acute ischaemic stroke is the result of an abrupt interruption of focal cerebral blood flow. In the majority of cases, this interruption is caused by an acute thromboembolism. Based on clinical experience in the treatment of acute coronary syndromes, platelet glycoprotein (GP) IIb/IIIa receptor antagonists alone, in combination with reduced doses of thrombolytic agents, or as complementary therapy for short-term mechanical interventions merit consideration as a class of agents with potential use in ischaemic stroke. Research to date and extrapolation from the cardiac literature suggest significant, but as yet unproven, potential for the use of GP IIb/IIIa receptor antagonists in the treatment of acute ischaemic stroke. This potential exists both at the site of the thromboembolic occlusion and at the distal microvascular level. This article reviews the scientific rationale and available evidence for the potential use of platelet GP IIb/IIIa receptor antagonists in acute ischaemic stroke.

UR - http://www.scopus.com/inward/record.url?scp=10044298299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044298299&partnerID=8YFLogxK

U2 - 10.2165/00023210-200418140-00003

DO - 10.2165/00023210-200418140-00003

M3 - Article

VL - 18

SP - 981

EP - 988

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 14

ER -